Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on June 30, 2026 reporting Item 7.01 (Regulation FD Disclosure). Optune Pax received CE Mark for adult locally advanced pancreatic cancer of exocrine origin.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Optune Pax received CE Mark for adult locally advanced pancreatic cancer of exocrine origin
- Approval covers use with gemcitabine and nab-paclitaxel under local guideline recommendations
- European regulatory clearance expands Optune Pax’s addressable pancreatic cancer market
- Disclosure is furnished under Regulation FD and not deemed filed under Exchange Act Section 18
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.